1. Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program 
Armando Santoro, MD, Mary E. O'Brien, MD, Rolf A. Stahel, MD, Kristiaan Nackaerts, MD, PhD, Paul Baas, MD, PhD, Meinolf Karthaus, MD, Wilfried Eberhardt, MD, Luis Paz-Ares, MD, PhD, Stein Sundstrom, MD, PhD, Yushan Liu, PhD, Veronique Ripoche, PhD, Johannes Blatter, MD, Carla M. Visseren-Grul, MD, Christian Manegold, MD 
Journal of Thoracic Oncology 
Volume 3, Issue 7, Pages (July 2008)
DOI: /JTO.0b013e31817c73d6
Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Patients with pleural mesothelioma who enrolled in the pemetrexed International Expanded Access Program. EAP, expanded access program; N, sample size; n, number of patients. The highlighted boxes are the patient population described in detail in this manuscript.
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c73d6)
Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan-Meier analysis of time to progressive disease (months) in chemonaïve evaluable patients with malignant pleural mesothelioma who received pemetrexed plus cisplatin (n = 745) or pemetrexed plus carboplatin (n = 752).
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c73d6)
Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Kaplan-Meier analysis of overall survival (months) in chemonaïve evaluable patients with malignant pleural mesothelioma who received pemetrexed plus cisplatin (n = 745) or pemetrexed plus carboplatin (n = 752).
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31817c73d6)
Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions